sphingosine kinase-2 inhibitor ABC294640
CTO 101504
Phase 1 small_molecule completed
Quick answer
sphingosine kinase-2 inhibitor ABC294640 for Pancreatic Cancer is a Phase 1 program (small_molecule) at Apogee Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Apogee Therapeutics
- Indication
- Pancreatic Cancer
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed